Ziopharm Oncology traded at $0.49 this Thursday May 26th, decreasing $0.01 or 1.74 percent since the previous trading session. Looking back, over the last four weeks, Ziopharm Oncology lost 12.85 percent. Over the last 12 months, its price fell by 83.83 percent. Looking ahead, we forecast Ziopharm Oncology to be priced at 0.49 by the end of this quarter and at 0.45 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Amgen 253.09 0.08 0.03% 7.56%
AstraZeneca 10,630.00 30.00 0.28% 31.23%
Baxter International 75.80 0.61 0.81% -7.35%
Biogen 204.27 1.91 0.94% -23.60%
Bioline Rx 1.44 0.20 15.99% -50.40%
Bristol-Myers Squibb 77.58 0.34 0.44% 18.06%
Corcept Therapeutics 20.22 0.28 1.40% -6.69%
Curis 0.72 -0.01 -1.11% -94.79%
Gilead Sciences 64.50 -0.52 -0.79% -2.13%
GlaxoSmithKline 1,776.20 1.20 0.07% 32.55%
Intercept Pharmaceuticals 17.16 0.34 2.02% 2.75%
Immunogen 3.73 0.26 7.49% -39.35%
Incyte Corp 76.03 -0.48 -0.63% -8.04%
Ionis Pharmaceuticals 37.34 0.48 1.30% 5.12%
J&J 179.54 -0.08 -0.04% 6.36%
Karyopharm Therapeutics 5.72 0.10 1.78% -38.63%
Merck & Co 92.35 -1.40 -1.49% 21.64%
Novartis 88.13 0.45 0.51% 10.93%
Pfizer 54.03 0.32 0.59% 39.78%
PTC Therapeutics 30.83 0.25 0.82% -22.58%
Regeneron Pharmaceuticals 683.17 -7.71 -1.12% 37.92%
Roche Holding 332.60 1.15 0.35% 6.50%
Sangamo BioSciences 3.60 0.18 5.26% -66.64%
TG Therapeutics 5.17 0.18 3.61% -84.95%
Verastem 1.26 0.02 1.61% -68.66%
Intrexon 1.30 0.06 4.84% -80.63%
Ziopharm Oncology 0.49 -0.01 -1.74% -83.83%

Indexes Price Day Year
USND 11741 305.91 2.68% -14.53%
US2000 1838 39.07 2.17% -19.13%

Ziopharm Oncology
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.